1. Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update
- Author
-
Ollivier Legrand, Jean El Cheikh, Mahmoud Aljurf, Radwan Massoud, Giorgia Battipaglia, Ali Bazarbachi, Riad Youniss, Mohamad Mohty, Syed Osman Ahmed, Battipaglia, G., Massoud, R., Ahmed, S. O., Legrand, O., El Cheikh, J., Youniss, R., Aljurf, M., Mohty, M., and Bazarbachi, A.
- Subjects
Oncology ,Male ,Cancer Research ,medicine.medical_treatment ,Hematopoietic stem cell transplantation ,medicine.disease_cause ,Cohort Studies ,0302 clinical medicine ,hemic and lymphatic diseases ,Medicine ,Maintenance treatment ,Mutation ,Remission Induction ,Hematopoietic Stem Cell Transplantation ,Myeloid leukemia ,hemic and immune systems ,Hematology ,Middle Aged ,Sorafenib ,Prognosis ,Combined Modality Therapy ,Survival Rate ,Leukemia ,Leukemia, Myeloid, Acute ,030220 oncology & carcinogenesis ,embryonic structures ,Female ,FLT3 Inhibitor ,medicine.drug ,Adult ,medicine.medical_specialty ,Adolescent ,Update ,Maintenance Chemotherapy ,03 medical and health sciences ,Young Adult ,Internal medicine ,Humans ,Transplantation, Homologous ,neoplasms ,Protein Kinase Inhibitors ,business.industry ,medicine.disease ,Allogeneic stem cell transplantation ,FLT3 mutated acute myeloid leukemia ,Graft-versus-host disease ,fms-Like Tyrosine Kinase 3 ,Fms-Like Tyrosine Kinase 3 ,Feasibility Studies ,business ,030215 immunology ,Follow-Up Studies - Abstract
Background: Patients diagnosed with acute myeloid leukemia (AML) with Fms-like tyrosine kinase 3 (FLT3) mutations have a very poor prognosis, despite use of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and salvage treatments. Patients and Methods: We previously reported the safety and efficacy of sorafenib, an FLT3 inhibitor, as a maintenance agent after allo-HSCT in patients diagnosed with AML with FLT3 mutations. We provide an update on the 27 patients with FLT3-mutated AML in our original report, who received sorafenib as a single maintenance agent. Results: Since our previous report, others have confirmed our reported significant overall survival and progression-free survival in patients who received sorafenib before and/or after allo-HSCT. In this update on the 27 patients with FLT3-mutated AML in our original report, we show persistence of the previously reported impressive long-term disease control. Conclusion: Our results, with longer follow-up than in our previous report, together with those of others, further support the use of sorafenib as a maintenance agent after allo-HSCT. Patients with acute myeloid leukemia (AML) with Fms-like tyrosine kinase 3 (FLT3) mutations have a very poor prognosis, despite use of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and salvage treatments. We previously reported the safety and efficacy of sorafenib, as a maintenance agent after allo-HSCT in 27 patients with FLT3-mutated AML. We provide an update on the patients in our original report, who received sorafenib as a single maintenance agent, and show persistence of the previously reported impressive long-term disease control. Our results continue to support the use of sorafenib as a maintenance agent after allo-HSCT.
- Published
- 2019